Current Hepatitis Reports

, Volume 5, Issue 3, pp 94–100

Antifibrotic targets and therapy in HCV


DOI: 10.1007/s11901-006-0011-2

Cite this article as:
Albanis, E. & Friedman, S.L. Curr hepatitis rep (2006) 5: 94. doi:10.1007/s11901-006-0011-2


Great progress has been made over the past 20 years in elucidating the mechanisms of hepatic fibrogenesis. The recognition of the hepatic stellate cell as the fibrogenic cell of the liver, as well as the recognition of key cytokines involved in fibrogenesis, has facilitated the development of targeted Antifibrotic therapies. Patients with chronic hepatitis C and fibrosis may benefit from these novel Antifibrotic therapies.

Copyright information

© Current Science Inc 2006

Authors and Affiliations

  1. 1.Division of Liver DiseasesMount Sinai School of MedicineNew YorkUSA